Researchers at the University of California San Diego have uncovered a key mechanism by which breast cancer spreads, potentially opening new avenues for treatment and highlighting the need for careful consideration of existing medications. The study, published recently, focuses on the role of a protein called TYK2 in responding to the physical characteristics of the environment surrounding tumors – a field known as mechanotransduction. Understanding how cancer cells interact with their surroundings is proving crucial in the fight against metastasis, the process by which cancer spreads to other parts of the body.
The findings are particularly relevant given that drugs designed to inhibit TYK2 are already being investigated as treatments for autoimmune diseases. This raises the possibility that these medications, although beneficial for autoimmune conditions, could inadvertently influence breast cancer progression, underscoring the importance of a holistic understanding of their effects. The core of the research centers on extracellular matrix rigidity and its impact on TYK2’s function.
The extracellular matrix (ECM) is the network of molecules that provides structural support to cells. It’s not a passive scaffold. it actively communicates with cells, influencing their behavior. Researchers discovered that TYK2 acts as a critical suppressor of breast cancer metastasis specifically in response to the stiffness of this matrix. When the ECM is less rigid, TYK2 resides on the cell membrane, effectively blocking the invasive tendencies of cancer cells. Although, when the ECM becomes stiffer – a common characteristic of tumor microenvironments – TYK2 becomes inactivated and moves inside the cell, removing this barrier and allowing cancer cells to invade and spread.
“This study reveals how extracellular matrix rigidity regulates breast cancer metastasis via TYK2 and provides new insights into how physical signals in the tumor microenvironment control cancer progression,” explained Zhimin Hu, PhD, the lead author of the study and a project scientist at the UC San Diego Moores Cancer Center.
TYK2 Inhibition and Metastasis in Animal Models
To test their hypothesis, the research team conducted experiments in mice. They found that inhibiting TYK2 with medication actually promoted breast cancer invasion and metastasis. This was a significant finding, as it demonstrated a direct link between TYK2 activity and the suppression of cancer spread. The results suggest that blocking TYK2 doesn’t always have the desired effect, particularly in the context of the tumor’s physical environment.
The implications extend beyond simply identifying a new target for cancer therapy. The research also suggests a potential risk for patients with certain types of non-invasive breast cancer who are being treated with TYK2 inhibitors for other conditions. These patients might be at a higher risk of developing invasive breast cancer, highlighting the need for increased surveillance and monitoring.
Implications for Autoimmune Disease Treatments
TYK2 inhibitors are currently under investigation for a range of autoimmune diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Several drugs targeting TYK2 have advanced through clinical trials. Deucravacitinib (Sotyktu), for example, was approved by the FDA in September 2023 for the treatment of moderate-to-severe plaque psoriasis in adults. The UC San Diego research suggests that clinicians should carefully consider the potential impact of these drugs on breast cancer risk, particularly in patients with pre-existing non-invasive breast cancer or those at high risk for developing the disease.
“Our results have significant implications for the clinical use of TYK2 inhibitors and underscore the importance of considering the mechanical microenvironment in cancer treatment,” said Jing Yang, PhD, the corresponding author and a professor of pharmacology at the UC San Diego School of Medicine, and also a member of the Moores Cancer Center. Which means that a one-size-fits-all approach to treatment may not be effective, and personalized medicine – tailoring treatment to the individual patient and their specific tumor characteristics – may be crucial.
Understanding Mechanotransduction in Cancer
The study contributes to a growing body of research highlighting the importance of mechanotransduction in cancer development and progression. Cancer cells aren’t simply responding to chemical signals; they’re also acutely aware of their physical surroundings. Factors like ECM stiffness, compression, and shear stress can all influence cancer cell behavior, affecting everything from growth and proliferation to invasion and metastasis. The National Cancer Institute recognizes mechanotransduction as a key area of cancer research.
Further research is needed to fully understand the complex interplay between TYK2, the ECM, and breast cancer metastasis. However, this study provides a valuable new piece of the puzzle, offering potential targets for future therapies and emphasizing the importance of considering the tumor microenvironment in cancer treatment strategies. The team plans to continue investigating the mechanisms underlying TYK2’s role in metastasis and explore ways to manipulate the ECM to prevent cancer spread.
The findings also emphasize the need for more sophisticated diagnostic tools that can assess the stiffness of the ECM in breast tumors. This information could help identify patients who are most likely to benefit from TYK2 inhibitors and those who might be at increased risk.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next step in this research will involve exploring potential strategies to restore TYK2 activity in stiff tumor microenvironments, potentially reversing the pro-metastatic effects of ECM rigidity. Researchers are also investigating whether similar mechanisms are at play in other types of cancer. Share your thoughts on this research in the comments below, and please share this article with anyone who might find it informative.
